These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32866193)

  • 1. Injectables' key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes.
    Decroo T; Maug AKJ; Hossain MA; Uwizeye C; Gumusboga M; Demeulenaere T; Ortuño-Gutiérrez N; de Jong BC; Van Deun A
    PLoS One; 2020; 15(8):e0238016. PubMed ID: 32866193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The perceived impact of isoniazid resistance on outcome of first-line rifampicin-throughout regimens is largely due to missed rifampicin resistance.
    Van Deun A; Decroo T; Kya Jai Maug A; Hossain MA; Gumusboga M; Mulders W; Ortuño-Gutiérrez N; Lynen L; de Jong BC; Rieder HL
    PLoS One; 2020; 15(5):e0233500. PubMed ID: 32421749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of multidrug-resistant tuberculosis with shorter treatment regimen in Niger: Nationwide programmatic achievements.
    Piubello A; Souleymane MB; Hassane-Harouna S; Yacouba A; Lempens P; Assao-Neino MM; Maman-Lawan I; Attaher S; Moustapha B; Soumana A; Gagara-Issoufou A; Ortuño-Gutiérrez N; Roggi A; Gumusboga M; Hamidou-Harouna Z; Dockx J; Mamadou S; de Jong BC; Decroo T; Van Deun A
    Respir Med; 2020 Jan; 161():105844. PubMed ID: 32056722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: A retrospective cohort study.
    Souleymane MB; Decroo T; Mamadou S; Soumana A; Lawan IM; Gagara-Issoufou A; Adehossi E; Ortuño-Gutiérrez N; Lynen L; Rigouts L; de Jong BC; Van Deun A; Piubello A
    Int Health; 2023 May; 15(3):258-264. PubMed ID: 35420123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients.
    Aung KJ; Van Deun A; Declercq E; Sarker MR; Das PK; Hossain MA; Rieder HL
    Int J Tuberc Lung Dis; 2014 Oct; 18(10):1180-7. PubMed ID: 25216831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Better programmatic outcome with the shorter regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in Guinea: A retrospective cohort study.
    Hassane-Harouna S; Cherif GF; Ortuno-Gutierrez N; Cisse D; Camara LM; Diallo BD; Camara S; Bangoura AM; Lynen L; Decroo T
    PLoS One; 2020; 15(8):e0237355. PubMed ID: 32776969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.
    Li J; Munsiff SS; Driver CR; Sackoff J
    Clin Infect Dis; 2005 Jul; 41(1):83-91. PubMed ID: 15937767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study].
    Yoshiyama T; Ogata H; Ito K; Aono A; Wada M
    Kekkaku; 2007 Feb; 82(2):95-101. PubMed ID: 17373318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmatic management of rifampicin-resistant tuberculosis with standard regimen in Cameroon: a retrospective cohort study.
    Jouego CG; Gils T; Piubello A; Mbassa V; Kuate A; Ngono A; Belinga E; Etoundi A; Tollo A; Makondi D; André E; Masumbe P; Lynen L; Noeske J; Decroo T
    Int J Infect Dis; 2022 Nov; 124():81-88. PubMed ID: 36108960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study.
    Shibeshi W; Sheth AN; Admasu A; Berha AB; Negash Z; Yimer G
    BMC Pharmacol Toxicol; 2019 May; 20(1):31. PubMed ID: 31122273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High success and low recurrence with shorter treatment regimen for multidrug-resistant TB in Nepal.
    Koirala S; Shah NP; Pyakurel P; Khanal M; Rajbhandari SK; Pun T; Shrestha B; Maharjan B; Karki S; Koirala S; Tamang KB; Roggi A; Kumar AMV; Ortuño-Gutiérrez N
    Public Health Action; 2021 Nov; 11(Suppl 1):38-45. PubMed ID: 34778014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.
    Bulabula ANH; Nelson JA; Musafiri EM; Machekano R; Sam-Agudu NA; Diacon AH; Shah M; Creswell J; Theron G; Warren RM; Jacobson KR; Chirambiza JP; Kalumuna D; Bisimwa BC; Katoto PDMC; Kaswa MK; Birembano FM; Kitete L; Grobusch MP; Kashongwe ZM; Nachega JB
    Clin Infect Dis; 2019 Sep; 69(8):1278-1287. PubMed ID: 30759187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB.
    Van Deun A; Decroo T; Kuaban C; Noeske J; Piubello A; Aung KJM; Rieder HL
    Int J Tuberc Lung Dis; 2019 Sep; 23(9):965-971. PubMed ID: 31615602
    [No Abstract]   [Full Text] [Related]  

  • 16. Factors associated with treatment outcome of MDR/RR-TB patients treated with shorter injectable based regimen in West Java Indonesia.
    Soeroto AY; Nurhayati RD; Purwiga A; Lestari BW; Pratiwi C; Santoso P; Kulsum ID; Suryadinata H; Ferdian F
    PLoS One; 2022; 17(1):e0263304. PubMed ID: 35089981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study.
    Schnippel K; Berhanu RH; Black A; Firnhaber C; Maitisa N; Evans D; Sinanovic E
    BMC Infect Dis; 2016 Oct; 16(1):593. PubMed ID: 27769174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extension of the intensive phase reduces relapse but not failure in a regimen with rifampicin throughout.
    Aung KJ; Declercq E; Ali MA; Naha S; Datta Roy SC; Taleb MA; Hossain MA; Rigouts L; Gumusboga A; Van Deun A
    Int J Tuberc Lung Dis; 2012 Apr; 16(4):455-61. PubMed ID: 22640511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Reduced mycobacterial resistance to antituberculous drugs in the experiment and clinic: immediate and long-term results].
    Belianin II; Shmelev EI
    Probl Tuberk Bolezn Legk; 2007; (2):31-8. PubMed ID: 17419333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.